PMID- 28008572
OWN - NLM
STAT- MEDLINE
DCOM- 20180227
LR  - 20181202
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 24
IP  - 5
DP  - 2017 May
TI  - Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy 
      for Patients with ypN0 Rectal Cancer.
PG  - 1304-1311
LID - 10.1245/s10434-016-5736-8 [doi]
AB  - BACKGROUND: Patients with ypN0 rectal cancer who have received preoperative 
      chemoradiotherapy can be divided into those who initially were node negative and 
      those whose positive nodes have been sterilized by preoperative therapy. The 
      long-term prognosis for ypN0 patients with sterilized lymph nodes (LNS) is 
      unknown. This study aimed to assess the prognostic value of LNS after 
      preoperative chemoradiotherapy for patients with ypN0 rectal cancer. METHODS: 
      From January 2007 to March 2014, 206 patients with ypN0 tumors of the mid or 
      lower rectum treated by chemoradiotherapy and radical surgery were enrolled in 
      the study. Of these 206 patients, 49 had ypN0 tumors with LNS (LNS+ group), and 
      157 had ypN0 tumors without LNS (LNS- group). The patients in both groups were 
      comparable in terms of tumor characteristics, type of chemoradiotherapy, type of 
      surgery, R0 resection rate, and postoperative complication rate. RESULTS: The 
      mean follow-up period was 40.5 +/- 27 months. The 1- and 3-year OS rates in the 
      LNS+ group were respectively 100 and 95.5% versus 99.4 and 91.6% in the LNS- 
      group (P = 0.549). The 1- and 3-year DFS rates in the LNS+ group were 
      respectively 100 and 94.2% versus 94.7 and 87.1% in the LNS- group (P = 0.117). 
      The multivariate analysis showed that the presence of LNS did not affect OS 
      (P = 0.918) or DFS (P = 0.209). CONCLUSIONS: The prognosis is excellent for 
      patients with ypN0 rectal cancer who have LNS after preoperative 
      chemoradiotherapy. The presence of LNS in ypN0 rectal cancer patients after 
      chemoradiotherapy should not be considered a factor for a poor prognosis.
FAU - Vychnevskaia, Karina
AU  - Vychnevskaia K
AD  - Department of Digestive and Oncologic Surgery, Ambroise Pare Hospital, APHP, UVSQ 
      University, Boulogne, France.
FAU - Dumont, Frederic
AU  - Dumont F
AD  - General Surgical Oncology Department, Gustave Roussy, Villejuif, France.
FAU - Agostini, Julie
AU  - Agostini J
AD  - Department of Digestive Surgery and Surgical Oncology, Bicetre Hospital, 
      Assistance Publique Hopitaux de Paris, Universite Paris-Sud, Le Kremlin Bicetre, 
      France.
FAU - Julie, Catherine
AU  - Julie C
AD  - Department of Pathology, Ambroise Pare Hospital, APHP, UVSQ University, Boulogne, 
      France.
FAU - Dartigues, Peggy
AU  - Dartigues P
AD  - Department of Pathology, Gustave Roussy, Villejuif, France.
FAU - Lazure, Thierry
AU  - Lazure T
AD  - Department of Pathology, Bicetre Hospital, APHP, Paris-Sud, University, Le 
      Kremlin Bicetre, France.
FAU - Boige, Valerie
AU  - Boige V
AD  - Department of Oncologic Medicine, Gustave Roussy, Villejuif, France.
FAU - Goere, Diane
AU  - Goere D
AD  - General Surgical Oncology Department, Gustave Roussy, Villejuif, France.
FAU - Brouquet, Antoine
AU  - Brouquet A
AD  - Department of Digestive Surgery and Surgical Oncology, Bicetre Hospital, 
      Assistance Publique Hopitaux de Paris, Universite Paris-Sud, Le Kremlin Bicetre, 
      France.
FAU - Penna, Christophe
AU  - Penna C
AD  - Department of Digestive Surgery and Surgical Oncology, Bicetre Hospital, 
      Assistance Publique Hopitaux de Paris, Universite Paris-Sud, Le Kremlin Bicetre, 
      France.
FAU - Peschaud, Frederique
AU  - Peschaud F
AD  - Department of Digestive and Oncologic Surgery, Ambroise Pare Hospital, APHP, UVSQ 
      University, Boulogne, France.
FAU - Benoist, Stephane
AU  - Benoist S
AD  - Department of Digestive Surgery and Surgical Oncology, Bicetre Hospital, 
      Assistance Publique Hopitaux de Paris, Universite Paris-Sud, Le Kremlin Bicetre, 
      France. stephane.benoist@bct.aphp.fr.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20161222
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Chemoradiotherapy, Adjuvant
MH  - Disease-Free Survival
MH  - Dose Fractionation, Radiation
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Lymph Nodes/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm, Residual
MH  - Preoperative Care
MH  - Rectal Neoplasms/*pathology/*therapy
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2016/12/23 06:00
MHDA- 2018/02/28 06:00
CRDT- 2016/12/24 06:00
PHST- 2016/10/07 00:00 [received]
PHST- 2016/12/23 06:00 [pubmed]
PHST- 2018/02/28 06:00 [medline]
PHST- 2016/12/24 06:00 [entrez]
AID - 10.1245/s10434-016-5736-8 [pii]
AID - 10.1245/s10434-016-5736-8 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2017 May;24(5):1304-1311. doi: 10.1245/s10434-016-5736-8. Epub 
      2016 Dec 22.